#2 Product of the Day
Launched

NoteV

An ambient AI scribe that drafts clinical notes in real time during patient visits.

NoteV screenshot
ABOUT THE PRODUCT

About NoteV

This ambient AI medical scribe listens to patient visits and drafts structured clinical notes in real time. It is built for clinicians who want to spend less time documenting and more time with patients. The product supports primary care, mental health, urgent care, pediatrics, dermatology, family medicine, and other specialties with workflow-specific note formats and terminology.

The main workflow is simple: start a visit on a phone, tablet, or desktop, let the system capture the conversation in the background, review the generated note, make edits if needed, then sign and sync the completed chart into the EHR. The page says this can reduce charting to under 60 seconds per visit and help clinicians finish documentation before the end of the day.

It supports SOAP notes, H&P reports, discharge summaries, procedure notes, referral letters, and custom formats. Notes can be pushed directly into supported EHR systems, including Epic, Cerner, Athenahealth, eClinicalWorks, and more than 50 integrations total. The product also highlights HIPAA compliance, SOC 2 Type II auditing, end-to-end encryption, a BAA on every plan, and deletion of visit audio after the note is drafted.

Pricing is publicly listed on the page, with a Solo plan starting at $29 per month and a Team plan at $99 per month. The page also mentions a 14-day free trial and cancel-anytime terms.

Key features:
- Ambient clinical documentation that drafts notes while you talk
- SOAP, H&P, discharge, procedure, referral, and custom note formats
- Direct EHR sync with Epic, Cerner, Athenahealth, eClinicalWorks, and 50+ systems
- Specialty-aware workflows for more than 30 medical specialties
- HIPAA compliance, SOC 2 Type II, end-to-end encryption, and BAA coverage
- Review, edit, sign, and push the completed note in about 60 seconds
- Available on phone, tablet, and desktop

COMMUNITY DISCUSSION

Comments

0 comments
No comments yet

Be the first to start the discussion.